Niagen Bioscience (NAGE) Share-based Compensation (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 59.63% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 79.02% increase from a year earlier, with the FY2025 full-year figure at $6.1 million, up 65.95% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.7 million, down from $1.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for NAGE reached as high as $1.9 million in Q1 2022 and fell as low as $735000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $1.3 million in 2023.
• Across the five-year window, Share-based Compensation plunged 34.2% in 2024 and jumped 138.91% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $1.3 million in 2022, then slipped by 21.79% to $1.0 million in 2023, then declined by 27.48% to $752000.0 in 2024, then surged by 132.45% to $1.7 million in 2025, then dropped by 1.83% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.